ReviewThe Lancet. Rheumatology2024
Cognitive impairment in individuals with rheumatic diseases: the role of systemic inflammation, immunomodulatory medications, and comorbidities.
Review in The Lancet. Rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Engineered nanosponges mitigate peripheral stress-induced neuroinflammation and restore cognitive function.bioRxiv : the preprint server for biology · 2026Article
- A Prospective Study Characterizing Cognitive Function in Patients With Inflammatory Bowel Disease.Clinical and translational gastroenterology · 2026Article
- Post-stroke rehabilitation in inflammatory rheumatic diseases: outcome measures, digital tools, and patient education perspectives.Rheumatology international · 2026Review
- NSAID use is associated with lower dementia and Alzheimer's disease prevalence and slower cognitive decline: A retrospective longitudinal analysis of the NACC cohort.medRxiv : the preprint server for health sciences · 2026Article
- Genome-Wide and Locus-Level Analyses Reveal Modest, Heterogeneous Genetic Sharing Between Alzheimer's Disease and Myasthenia Gravis.International journal of molecular sciences · 2026Article
- When Dryness Extends to the Brain: Brain-Related Non-Sicca Manifestations of Sjögren's Disease.Journal of clinical medicine · 2026Review
- Association of Frailty and Delirium with Hospitalization Outcomes Among Older Adults With Rheumatic Diseases.ACR open rheumatology · 2026Article
- Exploring Factors Associated With Cognitive Impairment in Rheumatoid Arthritis.Arthritis care & research · 2026Article
- Bioinformatic Analysis of microRNAs Associated with Chemotherapy-Induced Cognitive Impairment: Integration of Gene Networks and Neuroinflammatory Pathways.Biomedicines · 2026Article
- Measuring what matters: challenges in pain assessment among people with dementia and rheumatic and musculoskeletal diseases.EULAR rheumatology open · 2026Review
- A decision tree-based algorithm for structured risk stratification of rare rheumatic diseases in a tertiary referral setting.Frontiers in medicine · 2026Article
- Reconciling conflicting challenges in older rheumatology patients: remedies from geriatric-rheumatology clinics.Therapeutic advances in musculoskeletal disease · 2026Article
- Differential associations of non-chronic and chronic pain with dementia risk: insights from a cohort study.Frontiers in neuroscience · 2026Article
- The impact of osteoarthritis and geriatric depression scale on mini-mental state examination trajectories over seven years.European journal of ageing · 2025Article
- Observational
- Article
- Pathogenic Crosstalk Between the Peripheral and Central Nervous System in Rheumatic Diseases: Emerging Evidence and Clinical Implications.International journal of molecular sciences · 2025Review
- Getting prepared for the silver wave: challenges in conducting rheumatic and musculoskeletal disease research in older adults.RMD open · 2025Article
- Understanding the multiple dimensions of ageing: 5Ms for the rheumatologist.The Lancet. Rheumatology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Inflammation is an important risk factor, a potential therapeutic target for cognitive decline and dementia, and an inherent feature of autoimmune and immune-mediated rheumatic diseases. The risk of cognitive impairment and dementia is increased in individuals with immune-mediated rheumatic diseases, particularly in those with cardiovascular risk factors and cardiovascular disease. Immunomodulatory medications have been associated with a reduced risk of dementia, but whether this effect is mediated through their anti-inflammatory immunomodulating properties or other mechanisms, such as cardiovascular risk reduction, is unclear. A better understanding of the role of chronic inflammation as a modifiable risk factor for cognitive performance in rheumatic diseases will help inform opportunities for the management of cognitive impairment in people with rheumatic diseases and other chronic inflammatory diseases. In this Series paper, we discuss the epidemiology, risk factors, and current evidence on the role of immunomodulatory medications in cognitive impairment and dementia in people with rheumatic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.